

Siamak Daneshmand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/586236/publications.pdf>

Version: 2024-02-01

366
papers

13,943
citations

26610

56
h-index

27389

106
g-index

375
all docs

375
docs citations

375
times ranked

11644
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	13.5	1,742
2	Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. <i>Journal of Urology</i> , 2016, 196, 1021-1029.	0.2	971
3	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. <i>European Urology</i> , 2016, 69, 300-310.	0.9	460
4	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	2.9	324
5	PROGNOSIS OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY: LONG-TERM RESULTS. <i>Journal of Urology</i> , 2004, 172, 2252-2255.	0.2	289
6	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
7	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , 2014, 113, 11-23.	1.3	274
8	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	0.8	268
9	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	0.9	235
10	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	5.1	225
11	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	0.9	214
12	Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 50-56.	0.2	212
13	Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. <i>Human Pathology</i> , 2007, 38, 1547-1552.	1.1	191
14	Robotic Intracorporeal Orthotopic Ileal Neobladder: Replicating Open Surgical Principles. <i>European Urology</i> , 2012, 62, 891-901.	0.9	170
15	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019, 202, 272-281.	0.2	157
16	Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2014, 191, 40-47.	0.2	153
17	RADICAL CYSTECTOMY FOR PRIMARY NEUROENDOCRINE TUMORS OF THE BLADDER: THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE. <i>Journal of Urology</i> , 2005, 174, 93-96.	0.2	142
18	A Critical Analysis of Perioperative Mortality From Radical Cystectomy. <i>Journal of Urology</i> , 2006, 175, 886-890.	0.2	139

#	ARTICLE	IF	CITATIONS
19	Endoscopic management of upper urinary tract transitional cell carcinoma. <i>Cancer</i> , 2003, 98, 55-60.	2.0	134
20	EphB4 Expression and Biological Significance in Prostate Cancer. <i>Cancer Research</i> , 2005, 65, 4623-4632.	0.4	129
21	Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery. <i>Journal of Clinical Oncology</i> , 2010, 28, 537-542.	0.8	128
22	Androgen deprivation therapy: evidence-based management of side effects. <i>BJU International</i> , 2013, 111, 543-548.	1.3	128
23	Benign retroperitoneal schwannoma: a case series and review of the literature. <i>Urology</i> , 2003, 62, 993-997.	0.5	124
24	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3490-3493.	0.8	124
25	PROGNOSTIC SIGNIFICANCE OF LYMPHOVASCULAR INVASION OF BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2005, 174, 103-106.	0.2	121
26	Lymph Node Dissection Technique Is More Important Than Lymph Node Count in Identifying Nodal Metastases in Radical Cystectomy Patients: A Comparative Mapping Study. <i>European Urology</i> , 2011, 60, 946-952.	0.9	121
27	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 543-557.	0.9	105
28	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. <i>BJU International</i> , 2012, 109, 846-854.	1.3	101
29	Contemporary Management of Postchemotherapy Testis Cancer. <i>European Urology</i> , 2012, 62, 867-876.	0.9	96
30	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 53-59.	0.2	95
31	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. <i>European Urology</i> , 2012, 62, 677-684.	0.9	93
32	Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. <i>Journal of Urology</i> , 2015, 194, 1209-1213.	0.2	90
33	90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. <i>World Journal of Urology</i> , 2017, 35, 907-911.	1.2	90
34	Urinary Functional Outcome Following Radical Cystoprostatectomy and Ileal Neobladder Reconstruction in Male Patients. <i>Journal of Urology</i> , 2013, 189, 1782-1788.	0.2	89
35	Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 117-127.	0.8	87
36	Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. <i>BJU International</i> , 2013, 112, E51-8.	1.3	82

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018, 199, 1158-1165.	0.2	82
38	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. <i>Journal of Clinical Oncology</i> , 2019, 37, 3090-3098.	0.8	81
39	The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. <i>BJU International</i> , 2014, 113, 887-893.	1.3	80
40	Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 361.e1-361.e6.	0.8	79
41	A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence. <i>Clinical Cancer Research</i> , 2014, 20, 1978-1989.	3.2	77
42	Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life. <i>European Urology</i> , 2016, 69, 247-253.	0.9	77
43	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
44	Preoperative Staging of Invasive Bladder Cancer With Dynamic Gadolinium-enhanced Magnetic Resonance Imaging: Results From a Prospective Study. <i>Urology</i> , 2012, 80, 1313-1318.	0.5	75
45	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020, 78, 719-730.	0.9	73
46	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?. <i>Journal of Urology</i> , 2016, 195, 886-893.	0.2	71
47	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	3.2	71
48	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	0.9	69
49	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014, 11, 589-596.	1.9	69
50	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. <i>BJU International</i> , 2013, 111, 249-255.	1.3	67
51	Adrenal myelolipoma: diagnosis and management. <i>Urology Journal</i> , 2006, 3, 71-4.	0.3	63
52	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 640-645.	0.2	61
53	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	0.9	61
54	Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2018, 199, 1452-1458.	0.2	61

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1737-1743.	0.8	57
56	Venous Thromboembolism Following Radical Cystectomy: Significant Predictors, Comparison of Different Anticoagulants and Timing of Events. <i>Journal of Urology</i> , 2015, 193, 565-569.	0.2	56
57	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	0.8	56
58	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 52.e1-52.e9.	0.8	55
59	Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. <i>Journal of Urology</i> , 2017, 197, 684-689.	0.2	52
60	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA – update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	1.9	51
61	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. <i>Cancer</i> , 2003, 98, 955-961.	2.0	49
62	Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 110-116.	0.8	49
63	Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2012, 19, 2388-2393.	0.7	48
64	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. <i>European Urology</i> , 2013, 63, 371-378.	0.9	47
65	Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 40-47.	0.8	47
66	Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens. <i>Journal of Urology</i> , 2013, 190, 1704-1709.	0.2	46
67	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
68	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). <i>Clinical Cancer Research</i> , 2021, 27, 2435-2441.	3.2	46
69	A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T₂ bladder cancer. <i>BJU International</i> , 2013, 111, 240-248.	1.3	45
70	Resection of the Inferior Vena Cava Without Reconstruction for Urologic Malignancies. <i>Urology</i> , 2009, 74, 1257-1262.	0.5	44
71	Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy. <i>BJU International</i> , 2014, 113, 554-560.	1.3	43
72	Distinctive Morphology of Renal Cell Carcinomas in Tuberous Sclerosis. <i>International Journal of Surgical Pathology</i> , 2010, 18, 409-418.	0.4	41

#	ARTICLE	IF	CITATIONS
73	Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Related Outcome Measures, 2014, 5, 63.	0.7	41
74	Urinary functional outcomes in female neobladder patients. World Journal of Urology, 2014, 32, 221-228.	1.2	41
75	Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer. Journal of Urology, 2015, 194, 433-440.	0.2	41
76	Improving selection of appropriate urinary diversion following radical cystectomy for bladder cancer. Expert Review of Anticancer Therapy, 2011, 11, 941-948.	1.1	40
77	Long-term Outcomes of Open Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer in the Prostate-specific Antigen Era. Urology, 2012, 79, 626-631.	0.5	40
78	Cost Analysis of the Enhanced Recovery After Surgery Protocol in Patients Undergoing Radical Cystectomy for Bladder Cancer. European Urology Focus, 2016, 2, 92-96.	1.6	40
79	SIUâ€“ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	1.2	40
80	Level III-IV Inferior Vena Caval Thrombectomy Without Cardiopulmonary Bypass: Long-Term Experience with Intrapericardial Control. Journal of Urology, 2014, 192, 682-689.	0.2	39
81	Gastrointestinal Complications Following Radical Cystectomy Using Enhanced Recovery Protocol. European Urology Focus, 2018, 4, 889-894.	1.6	39
82	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cellâ€“free DNA results. Cancer, 2020, 126, 2597-2606.	2.0	39
83	New molecular markers for bladder cancer detection. Current Opinion in Urology, 2004, 14, 259-264.	0.9	38
84	Outcomes After Urothelial Recurrence in Bladder Cancer Patients Undergoing Radical Cystectomy. Urology, 2014, 84, 1420-1426.	0.5	38
85	ENDOSCOPIC MANAGEMENT OF RENAL HEMANGIOMA. Journal of Urology, 2002, 167, 488-489.	0.2	37
86	Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics. Frontiers in Endocrinology, 2012, 3, 182.	1.5	36
87	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. Journal of Urology, 2016, 196, 1627-1633.	0.2	36
88	Prospective Evaluation of Continence Following Radical Cystectomy and Orthotopic Urinary Diversion Using a Validated Questionnaire. Journal of Urology, 2016, 196, 1685-1691.	0.2	36
89	Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients. World Journal of Urology, 2018, 36, 775-781.	1.2	36
90	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. European Urology, 2021, 79, 16-19.	0.9	36

#	ARTICLE	IF	CITATIONS
91	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. <i>Cancers</i> , 2021, 13, 4378.	1.7	35
92	Reproductive Organ Involvement in Female Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2134-2138.	0.2	34
93	Incisional and Parastomal Hernia following Radical Cystectomy and Urinary Diversion: The University of Southern California Experience. <i>Journal of Urology</i> , 2016, 196, 777-781.	0.2	34
94	Puboprostatic Sling Repair for Treatment of Urethral Incompetence in Adult Neurogenic incontinence. <i>Journal of Urology</i> , 2003, 169, 199-202.	0.2	33
95	Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: Results from a prospective lymph node mapping study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 24.e13-24.e19.	0.8	33
96	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	0.8	33
97	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , 2016, 196, 1036-1041.	0.2	33
98	Factors influencing the choice of urinary diversion in patients undergoing radical cystectomy. <i>BJU International</i> , 2010, 106, 654-657.	1.3	31
99	Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e265-e269.	0.9	31
100	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
101	Diagnosis and Staging of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 531-541.	0.9	31
102	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. <i>Journal of Urology</i> , 2022, 207, 302-313.	0.2	31
103	Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. <i>Urology</i> , 2006, 67, 1247-1252.	0.5	30
104	Critical Evaluation of the American Joint Committee on Cancer TNM Nodal Staging System in Patients with Lymph Node-Positive Disease after Radical Cystectomy. <i>European Urology</i> , 2012, 62, 671-676.	0.9	30
105	Growing teratoma syndrome: Clinical and radiographic characteristics. <i>International Journal of Urology</i> , 2014, 21, 905-908.	0.5	30
106	Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity. <i>European Urology</i> , 2017, 72, 814-820.	0.9	30
107	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. <i>European Urology</i> , 2020, 77, 669-670.	0.9	30
108	Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. <i>European Urology</i> , 2019, 76, 238-243.	0.9	29

#	ARTICLE	IF	CITATIONS
109	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
110	Venous Resection in Urological Surgery. <i>Journal of Urology</i> , 2008, 180, 2338-2342.	0.2	28
111	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
112	Utility and significance of ureteric frozen section analysis during radical cystectomy. <i>BJU International</i> , 2016, 117, 463-468.	1.3	28
113	SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 375-375.	0.8	28
114	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	2.6	28
115	Review of techniques to remove a Foley catheter when the balloon does not deflate. <i>Urology</i> , 2002, 59, 127-129.	0.5	27
116	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.2	27
117	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , 2013, 111, 74-84.	1.3	26
118	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , 2021, 4, 12-19.	2.6	26
119	SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4506-4506.	0.8	26
120	PROGNOSIS OF SEMINAL VESICLE INVOLVEMENT BY TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2004, 172, 81-84.	0.2	25
121	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. <i>European Urology Oncology</i> , 2018, 1, 223-230.	2.6	25
122	Continent right colon reservoir using a cutaneous appendicostomy. <i>Urology</i> , 2004, 63, 577-580.	0.5	24
123	Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1441-1447.	0.8	24
124	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. <i>BMC Cancer</i> , 2014, 14, 966.	1.1	24
125	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. <i>European Urology Focus</i> , 2018, 4, 245-251.	1.6	24
126	Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy. <i>Journal of Urology</i> , 2019, 202, 1001-1007.	0.2	23

#	ARTICLE	IF	CITATIONS
127	Female reproductive organ-sparing radical cystectomy. <i>Current Opinion in Urology</i> , 2015, 25, 105-110.	0.9	21
128	Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies. <i>Current Urology Reports</i> , 2017, 18, 34.	1.0	21
129	Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 765-773.	0.8	21
130	Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 48-56.	0.8	21
131	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patients undergoing urologic oncology surgery: a systematic review. <i>World Journal of Urology</i> , 2022, 40, 1325-1342.	1.2	21
132	Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. <i>Prostate</i> , 2016, 76, 1239-1256.	1.2	20
133	Gastrointestinal Complications in Patients Who Undergo Radical Cystectomy with Enhanced Recovery Protocol. <i>Current Urology Reports</i> , 2016, 17, 50.	1.0	20
134	Satisfaction With Testicular Prosthesis After Radical Orchiectomy. <i>Urology</i> , 2018, 114, 128-132.	0.5	20
135	Management of residual mass in nonseminomatous germ cell tumors following chemotherapy. <i>Therapeutic Advances in Urology</i> , 2011, 3, 163-171.	0.9	19
136	Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: Prognostic value in invasive urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 648-656.	0.8	19
137	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. <i>World Journal of Urology</i> , 2015, 33, 1419-1428.	1.2	19
138	Intraoperative Renal Cell Carcinoma Tumor Embolization to the Right Atrium: Incidental Diagnosis by Transesophageal Echocardiography. <i>Anesthesia and Analgesia</i> , 2006, 102, 378-379.	1.1	18
139	Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer. <i>BJU International</i> , 2013, 111, E167-72.	1.3	18
140	Enhanced recovery pathway following radical cystectomy. <i>Current Opinion in Urology</i> , 2014, 24, 135-139.	0.9	18
141	Orthotopic urinary diversion. <i>Current Opinion in Urology</i> , 2015, 25, 545-549.	0.9	18
142	The association between intraoperative fluid intake and postoperative complications in patients undergoing radical cystectomy with an enhanced recovery protocol. <i>World Journal of Urology</i> , 2018, 36, 401-407.	1.2	18
143	Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma. <i>Advances in Urology</i> , 2018, 2018, 1-5.	0.6	18
144	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18

#	ARTICLE	IF	CITATIONS
145	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1 α 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3 α altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	0.9	18
146	The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1007-1016.	1.1	17
147	Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. <i>BJU International</i> , 2013, 111, E37-42.	1.3	17
148	Validation of Surveillance, Epidemiology, and End Results TNM staging for testicular germ cell tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1341-1346.	0.8	17
149	Role of surgical resection for refractory germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 370-378.	0.8	17
150	Radical cystectomy with super-extended lymphadenectomy: impact of separate vs <i>en bloc</i> lymph node submission on analysis and outcomes. <i>BJU International</i> , 2016, 117, 253-259.	1.3	17
151	Adult genitourinary sarcoma: A population-based analysis of clinical characteristics and survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 334-343.	0.8	17
152	Urinary tract infections following radical cystectomy with enhanced recovery protocol: A prospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 75.e9-75.e14.	0.8	17
153	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	1.2	16
154	Midline Extraperitoneal Approach for Retroperitoneal Lymph Node Dissection for Testicular Germ Cell Tumor. <i>Urology</i> , 2012, 80, 941-945.	0.5	16
155	Reprogramming of the human intestinal epigenome by surgical tissue transposition. <i>Genome Research</i> , 2014, 24, 545-553.	2.4	16
156	Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 711-716.	0.9	16
157	Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. <i>BJU International</i> , 2019, 123, 35-41.	1.3	16
158	Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors. <i>Urology</i> , 2019, 126, 140-144.	0.5	16
159	Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 784-790.	0.8	16
160	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 119-125.	2.6	16
161	Discrepancies in the Recommended Management of Adrenal Incidentalomas by Various Guidelines. <i>Journal of Urology</i> , 2021, 205, 52-59.	0.2	16
162	Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. <i>European Urology Focus</i> , 2020, 6, 639-641.	1.6	16

#	ARTICLE	IF	CITATIONS
163	Application of the Yang-Monti Channel in Adult Continent Cutaneous Urinary Diversion. <i>Urology</i> , 2008, 72, 828-831.	0.5	15
164	Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2013, 40, 233-247.	0.8	15
165	Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998â€”2011). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 487.e7-487.e11.	0.8	15
166	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
167	Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. <i>Clinical Epigenetics</i> , 2021, 13, 84.	1.8	15
168	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 207, 70-76.	0.2	15
169	Colourachal Fistula in an Adult Presenting with Feculent Umbilical Drainage. <i>Journal of Urology</i> , 2003, 170, 184-184.	0.2	14
170	Null Association Between Histology of First and Second Primary Malignancies in Men With Bilateral Testicular Germ Cell Tumors. <i>American Journal of Epidemiology</i> , 2013, 178, 1240-1245.	1.6	14
171	Role of Extraretroperitoneal Surgery in Patients with Metastatic Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 369-380.	0.8	14
172	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 689-695.e2.	0.9	14
173	Continent Cutaneous Diversion. <i>Urologic Clinics of North America</i> , 2018, 45, 55-65.	0.8	14
174	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	0.8	14
175	Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor. <i>Urologic Clinics of North America</i> , 2019, 46, 389-398.	0.8	14
176	Assessing trends in urinary diversion after radical cystectomy for bladder cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e1-180.e9.	0.8	14
177	Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence. <i>Journal of Urology</i> , 2003, 169, 199-202.	0.2	14
178	Radical cystectomy with orthotopic neobladder reconstruction following prior radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 741-745.	1.2	13
179	Outcome in patients with exclusive carcinoma <i>in situ</i> (<sc>CIS</sc>) after radical cystectomy. <i>BJU International</i> , 2014, 113, 65-69.	1.3	13
180	Enhanced Endoscopy in Bladder Cancer. <i>Current Urology Reports</i> , 2018, 19, 84.	1.0	13

#	ARTICLE	IF	CITATIONS
181	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 796.e1-796.e6.	0.8	13
182	Effectiveness of extended pelvic lymphadenectomy in the survival of prostate cancer: a systematic review and meta-analysis. <i>Central European Journal of Urology</i> , 2018, 71, 262-269.	0.2	13
183	Frailty and preoperative risk assessment before radical cystectomy. <i>Current Opinion in Urology</i> , 2019, 29, 216-219.	0.9	12
184	Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. <i>Urology</i> , 2005, 65, 1008-1012.	0.5	11
185	The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 842-847.	0.8	11
186	Androgen-Producing Testicular Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, e634-e635.	0.8	11
187	Restrictive transfusion in radical cystectomy is safe. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 528.e15-528.e21.	0.8	11
188	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 90-98.e1.	0.9	11
189	The impact of patient-related nonmodifiable factors on perioperative outcomes following radical cystectomy with enhanced recovery protocol. <i>Therapeutic Advances in Urology</i> , 2018, 10, 393-401.	0.9	11
190	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 1-11.	0.8	11
191	Prospective evaluation of blueâ€light flexible cystoscopy with hexaminolevulinate in nonâ€muscleâ€invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	1.3	11
192	The Prognostic Significance of S‐Phase Analysis in Stage Ta/T1 Bladder Cancer. <i>European Urology</i> , 2000, 37, 595-600.	0.9	10
193	Renal angiomyolipoma with liposarcomatous transformation: A case report and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 425-427.	0.8	10
194	Use of Nonabsorbable Staples for Urinary Diversion: A Step in the Wrong Direction. <i>Urologia Internationalis</i> , 2013, 90, 125-129.	0.6	10
195	Radical cystectomy and orthotopic urinary diversion in male patients with ^{pT4a} urothelial bladder carcinoma: Oncological outcomes. <i>International Journal of Urology</i> , 2013, 20, 1229-1233.	0.5	10
196	Significance of perivesical lymph nodes in radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1158-1165.	0.8	10
197	Is Frozen Section Analysis of Ureteral Margins at Time of Radical Cystectomy Useful?. <i>Current Urology Reports</i> , 2015, 16, 38.	1.0	10
198	Oncological Outcomes After Radical Prostatectomy for Highâ€Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases. <i>Prostate</i> , 2017, 77, 743-748.	1.2	10

#	ARTICLE	IF	CITATIONS
199	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	1.3	10
200	Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. <i>Urology</i> , 2020, 142, 155-160.	0.5	10
201	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	1.3	10
202	Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocol. <i>International Urology and Nephrology</i> , 2021, 53, 1827-1833.	0.6	10
203	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS603-TPS603.	0.8	10
204	Bladder Recurrence Following Diagnostic Ureteroscopy in Patients Undergoing Nephroureterectomy for Upper Tract Urothelial Cancer: Is Ureteral Access Sheath Protective?. <i>Urology</i> , 2022, 160, 142-146.	0.5	10
205	Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. <i>Future Oncology</i> , 2022, 18, 2599-2614.	1.1	10
206	Primary Renal Carcinoid Tumor. <i>Scientific World Journal</i> , The, 2004, 4, 378-380.	0.8	9
207	Mesenteric Lymphadenopathy in Testicular Germ Cell Tumor. <i>Urology</i> , 2014, 83, e7-e8.	0.5	9
208	Orthotopic urinary diversion in the elderly. <i>World Journal of Urology</i> , 2016, 34, 13-18.	1.2	9
209	Lymph node dissection in bladder cancer: Where do we stand?. <i>World Journal of Urology</i> , 2017, 35, 527-533.	1.2	9
210	Feasibility of expert and crowd-sourced review of intraoperative video for quality improvement of intracorporeal urinary diversion during robotic radical cystectomy. <i>Canadian Urological Association Journal</i> , 2017, 11, 331-6.	0.3	9
211	Internal audit of an enhanced recovery after surgery protocol for radical cystectomy. <i>World Journal of Urology</i> , 2020, 38, 3131-3137.	1.2	9
212	Perioperative Outcome of Suprarenal Resection of Vena Cava Without Reconstruction in Urologic Malignancies: A Case Series and Review of the Literature. <i>Urology</i> , 2020, 142, 146-154.	0.5	9
213	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5095-TPS5095.	0.8	9
214	Sarcomatoid renal cell carcinoma with massive osteosarcomatous differentiation: an unusual image in clinical urology. <i>Urology</i> , 2003, 61, 1031-1032.	0.5	8
215	Current clinical trials in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 289-292.	0.8	8
216	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017, 35, 1729-1736.	1.2	8

#	ARTICLE	IF	CITATIONS
217	Modern Management of Testicular Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 273-308.	0.2	8
218	Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer. <i>Urology</i> , 2019, 133, 157-163.	0.5	8
219	Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors. <i>Current Opinion in Urology</i> , 2020, 30, 251-257.	0.9	8
220	The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 206, 1380-1389.	0.2	8
221	Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. <i>International Urology and Nephrology</i> , 2019, 51, 435-441.	0.6	8
222	ENDOSCOPIC MANAGEMENT OF RENAL HEMANGIOMA. <i>Journal of Urology</i> , 2002, 167, 488-489.	0.2	8
223	Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4549-4549.	0.8	8
224	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring <i>FGFR3</i> alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600.	0.8	8
225	Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy. <i>Current Urology Reports</i> , 2016, 17, 62.	1.0	7
226	Factors influencing intraoperative conversion from planned orthotopic to non-orthotopic urinary diversion during radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 1851-1855.	1.2	7
227	Bladder Cancer: Advances and Innovations. <i>European Urology Focus</i> , 2020, 6, 613-614.	1.6	7
228	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4510-4510.	0.8	7
229	Clinical stage II seminoma: management options. <i>World Journal of Urology</i> , 2022, 40, 343-348.	1.2	7
230	Risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit. <i>BJU International</i> , 2022, 130, 381-388.	1.3	7
231	Evaluation and Preservation of Fertility in Patients with Testicular Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 25-29.	0.7	6
232	Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study. <i>World Journal of Urology</i> , 2018, 36, 1233-1239.	1.2	6
233	Current controversies on the role of lymphadenectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 193-200.	0.8	6
234	National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. <i>European Urology Oncology</i> , 2020, 3, 343-350.	2.6	6

#	ARTICLE	IF	CITATIONS
235	Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 133.e1-133.e8.	0.8	6
236	Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study. <i>Cancer Medicine</i> , 2021, 10, 3004-3012.	1.3	6
237	Development and Validation of an Objective Scoring Tool to Evaluate Surgical Dissection: Dissection Assessment for Robotic Technique (DART). <i>Urology Practice</i> , 2021, 8, 596-604.	0.2	6
238	Re: Appendiceal substitution following right proximal ureter injury. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009, 35, 90-91.	0.7	6
239	An emerging role for immuno-nutrition in patients undergoing radical cystectomy. <i>Nature Reviews Urology</i> , 2022, 19, 1-2.	1.9	6
240	Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry. <i>BJU International</i> , 2022, 130, 62-67.	1.3	6
241	Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 409-409.	0.8	6
242	Long-term renal function in patients with chronic kidney disease following radical cystectomy and orthotopic neobladder. <i>BJU International</i> , 2022, 130, 200-207.	1.3	6
243	Minimally Invasive Postchemotherapy Retroperitoneal Lymph Node Dissection: Caution and Prudence. <i>European Urology</i> , 2013, 63, 1018-1019.	0.9	5
244	Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bNOMO prostate cancer in the prostate-specific antigen era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 85-91.	0.8	5
245	Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome. <i>Urology</i> , 2016, 97, 40-45.	0.5	5
246	Enhanced Recovery After Surgery Pathways. <i>Urologic Clinics of North America</i> , 2018, 45, 229-239.	0.8	5
247	Molecular Prognostication in Bladder Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 165-191.	0.2	5
248	Factors influencing ICU admission and associated outcome in patients undergoing radical cystectomy with enhanced recovery pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 572.e13-572.e19.	0.8	5
249	Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. <i>European Urology Focus</i> , 2020, 7, 1137-1142.	1.6	5
250	A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 614927.	1.3	5
251	Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4519-4519.	0.8	5
252	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 35-42.	0.9	5

#	ARTICLE	IF	CITATIONS
253	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 344.e1-344.e9.	0.8	5
254	Chemoresponsive Liver Hemangioma in a Patient With a Metastatic Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2011, 29, e842-e844.	0.8	4
255	Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus and Metastatic Caval Wall Invasion. <i>Urology</i> , 2012, 79, e6-e8.	0.5	4
256	Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 173-179.	1.2	4
257	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019, 125, 3853-3863.	2.0	4
258	Management of extraretroperitoneal masses in germ cell tumor. <i>Current Opinion in Urology</i> , 2019, 29, 33-41.	0.9	4
259	High-grade T1 Urothelial Carcinoma: Where Do We Stand?. <i>Current Urology Reports</i> , 2019, 20, 79.	1.0	4
260	Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. <i>Journal of Endourology</i> , 2021, 35, 647-651.	1.1	4
261	Macro and microeconomics of blue light cystoscopy with CYSVIEWA® in non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e7-10.e12.	0.8	4
262	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
263	Validation of the COBRA nomogram for the prediction of cancer specific survival in patients treated with radical cystectomy for bladder cancer: An international wide cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2646-2650.	0.5	4
264	Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 324-324.	0.8	4
265	Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5038-5038.	0.8	4
266	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. <i>Journal of Urology</i> , 2022, 207, 534-540.	0.2	4
267	Oncological outcomes following radical cystectomy for urothelial carcinoma of the bladder with positive lymph nodes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 584-584.	0.8	4
268	Intricacies of retroperitoneal lymph node dissection for testis cancer. <i>Current Opinion in Urology</i> , 2021, Publish Ahead of Print, 24-30.	0.9	4
269	Association between use of ERAS protocols and complications after radical cystectomy. <i>World Journal of Urology</i> , 2022, 40, 1311-1316.	1.2	4
270	Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1769-1779.	1.1	4

#	ARTICLE	IF	CITATIONS
271	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Review of Anticancer Therapy, 2006, 6, 1639-1651.	1.1	3
272	1911 FACTORS INFLUENCING LYMPH NODE YIELD DURING RADICAL CYSTECTOMY WITH EXTENDED PELVIC LYMPHADENECTOMY: SINGLE-INSTITUTION EXPERIENCE WITH A STANDARDIZED DISSECTION TEMPLATE. Journal of Urology, 2012, 187, .	0.2	3
273	Management of the Continent Cutaneous Stomal Complications. Current Bladder Dysfunction Reports, 2012, 7, 294-301.	0.2	3
274	Urinary diversion 2015. Current Opinion in Urology, 2015, 25, 543-544.	0.9	3
275	Continent Urinary Diversion in the Elderly. Current Geriatrics Reports, 2015, 4, 1-6.	1.1	3
276	Surgical strategies for postchemotherapy testis cancer. Translational Andrology and Urology, 2020, 9, S74-S82.	0.6	3
277	Stoma complications and quality of life in patients with Indiana pouch versus appendico/neo-appendico-umbilicostomy urinary diversions. World Journal of Urology, 2021, 39, 1521-1529.	1.2	3
278	Predictors of need for catheterisation and urinary retention after radical cystectomy and orthotopic neobladder in male patients. BJU International, 2021, 128, 304-310.	1.3	3
279	Evaluation of Bowel Function Following Radical Cystectomy and Urinary Diversion Using Two Validated Questionnaires: What Are the Effects on Quality of Life?. Urology, 2021, 156, 279-284.	0.5	3
280	Patient Reported Sexual Function Outcomes in Male Patients Following Open Radical Cystoprostatectomy and Urinary Diversion. Urology, 2021, , .	0.5	3
281	Safety and feasibility of urological procedures in Jehovahâ€™s Witness patients. International Journal of Urology, 2022, 29, 83-88.	0.5	3
282	Management of difficult germ-cell tumors. Oncology, 2006, 20, 1565-70, 1575; discussion 1575-6.	0.4	3
283	Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 381.e9-381.e16.	0.8	3
284	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 382.e1-382.e6.	0.8	3
285	Adenomatous Polyp of the Verumontanum Causing Bladder Outlet Obstruction. Scientific World Journal, The, 2004, 4, 89-91.	0.8	2
286	Open Partial Nephrectomy for Pediatric Renovascular Hypertension. Scientific World Journal, The, 2009, 9, 287-290.	0.8	2
287	THE VALUE OF EXTENDED TRANSURETHRAL RESECTION OF BLADDER TUMOUR (TURBT) IN THE TREATMENT OF BLADDER CANCER. BJU International, 2012, 110, E80.	1.3	2
288	Short-term Change in Renal Function in Patients Undergoing Continent vs Noncontinent Urinary Diversions. UroToday International Journal, 2013, 06, .	0.1	2

#	ARTICLE	IF	CITATIONS
289	Growing Teratoma Syndrome of Testicular Origin. <i>Urology</i> , 2019, 123, 20-23.	0.5	2
290	Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto's Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.06.039 . European Urology, 2020, 78, e190-e191.	0.9	2
291	Perioperative complications and oncological outcomes following radical cystectomy among different racial groups: A long-term, single-center study. <i>Canadian Urological Association Journal</i> , 2020, 14, E493-E498.	0.3	2
292	Detecting Invisible Bladder Cancers With Blue Light Cystoscopy. <i>Urology</i> , 2020, 139, e8-e9.	0.5	2
293	Zero, Some Chemotherapy Game in Early-Stage Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2214-2215.	0.8	2
294	Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation. <i>Urology</i> , 2021, 148, 198-202.	0.5	2
295	Multiparametric cystoscopy: is the future here yet?. <i>Translational Andrology and Urology</i> , 2021, 10, 1-6.	0.6	2
296	Vena Cava Tumor Thrombus Associated With Renal Angiomyolipoma in a Jehovah's Witness Patient. <i>Urology</i> , 2021, 156, e86-e87.	0.5	2
297	MicroRNA-371a-3p as a blood-based biomarker in testis cancer. <i>Asian Journal of Urology</i> , 2021, 8, 400-406.	0.5	2
298	Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesions. <i>Videourology (New Rochelle, N Y)</i> , 2018, 32, .	0.1	2
299	Predicting survival after radical cystectomy: Validation of the SPARC score.. <i>Journal of Clinical Oncology</i> , 2015, 33, 326-326.	0.8	2
300	Re: Prediagnosis Prostate Specific Antigen Velocity is Associated With Risk of Prostate Cancer Progression Following Brachytherapy and External Beam Radiation Therapy. <i>Journal of Urology</i> , 2007, 177, 2396-2396.	0.2	1
301	753 AGE IS NOT A CONTRAINDICATION FOR AN ORTHOTOPIC ILEAL NEOBLADDER FOLLOWING RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2010, 183, .	0.2	1
302	1137 THE IMPACT OF INTESTINAL URINARY DIVERSION ON RENAL FUNCTION. <i>Journal of Urology</i> , 2011, 185, .	0.2	1
303	Colocalcystomy for Repair of Ureterojejunal Fistula. <i>Urology</i> , 2012, 79, e12-e14.	0.5	1
304	Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. <i>BJU International</i> , 2012, 110, 1324-1324.	1.3	1
305	Orthotopic Urinary Diversion in Men. , 2017, , 11-24.		1
306	Vena Cavoscopy in the Assessment of Intraluminal Vena Caval Tumor Involvement. <i>Urology</i> , 2018, 113, 105-109.	0.5	1

#	ARTICLE	IF	CITATIONS
307	Advanced Testis Cancer. <i>European Urology Focus</i> , 2019, 5, 710-712.	1.6	1
308	Voiding Dysfunction After Neobladder Urinary Diversion. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 38-43.	0.2	1
309	Editorial. <i>Current Opinion in Urology</i> , 2020, 30, 234.	0.9	1
310	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e473-e477.	0.9	1
311	Enhanced recovery after cystectomy in patients with preoperative narcotic use. <i>Canadian Urological Association Journal</i> , 2021, 15, E563-E568.	0.3	1
312	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2021, 41, 3851-3857.	0.5	1
313	Stomal Complications. , 2017, , 121-141.		1
314	Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 295-295.	0.8	1
315	Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4568-4568.	0.8	1
316	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	0.8	1
317	Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-526.	0.8	1
318	Mesenteric lymphadenopathy in patients with germ cell tumor.. <i>Journal of Clinical Oncology</i> , 2012, 30, 347-347.	0.8	1
319	Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4587-4587.	0.8	1
320	Comparison between oncological outcomes of primary versus salvage radical cystectomy for urothelial carcinoma of the bladder.. <i>Journal of Clinical Oncology</i> , 2020, 38, 585-585.	0.8	1
321	Active surveillance for low-risk prostate cancer " in pursuit of a standardized protocol. <i>Central European Journal of Urology</i> , 2020, 73, 123-126.	0.2	1
322	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	1.7	1
323	Metastatic adenocarcinoma of the prostate with a testicular mass and cutaneous nodules. <i>BJU International</i> , 2003, 92, e61.	1.3	0
324	Re: Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer in Older Men. <i>European Urology</i> , 2008, 54, 1201-1202.	0.9	0

#	ARTICLE	IF	CITATIONS
325	Editorial Comment. Urology, 2010, 76, 1001.	0.5	0
326	The Role of Photodocumentation in Surveillance Cystoscopy for Bladder Cancer. UroToday International Journal, 2011, 04, .	0.1	0
327	Editorial Comment. Urology, 2012, 79, 481.	0.5	0
328	Editorial Comment. Urology, 2012, 80, 639.	0.5	0
329	Conversion From Incontinent Conduit to Continent Cutaneous Reservoir After Renal Transplant. Urology, 2013, 81, 1086-1089.	0.5	0
330	Editorial Comment. Journal of Urology, 2013, 190, 927-927.	0.2	0
331	Editorial Comment. Urology, 2013, 82, 1346.	0.5	0
332	Editorial Comment. Journal of Urology, 2016, 195, 1716-1716.	0.2	0
333	Readmission Following Radical Cystectomy: A Ray of Light in the "Black Box". European Urology Focus, 2018, 4, 718-719.	1.6	0
334	Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy. Scandinavian Journal of Urology, 2019, 53, 123-128.	0.6	0
335	Preface. Urologic Clinics of North America, 2019, 46, xiii.	0.8	0
336	Quality reporting in postchemotherapy retroperitoneal lymph node dissection. Cancer, 2020, 126, 4825-4825.	2.0	0
337	EDITORIAL COMMENT. Urology, 2020, 140, 120-121.	0.5	0
338	AUTHOR REPLY. Urology, 2020, 142, 154.	0.5	0
339	Radical Cystectomy. , 2021, , 139-175.		0
340	A Massive Penile Tumor. Urology, 2021, 154, e5-e6.	0.5	0
341	Renal Brucellosis in a Herniated Kidney. UroToday International Journal, 2010, 03, .	0.1	0
342	Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California. Journal of Clinical Oncology, 2012, 30, 301-301.	0.8	0

#	ARTICLE	IF	CITATIONS
343	The influence of variant histology on survival outcomes of radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2012, 30, 278-278.	0.8	0
344	The impact of preoperative ASA and serum albumin on early complication and survival rate of patients undergoing radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2012, 30, 313-313.	0.8	0
345	Clinical validation of the 7th AJCC-TNM nodal staging system in lymph node-positive patients undergoing radical cystectomy.. Journal of Clinical Oncology, 2012, 30, 4588-4588.	0.8	0
346	Mortality from other malignancies in bladder cancer survivors.. Journal of Clinical Oncology, 2012, 30, 4589-4589.	0.8	0
347	Evaluation of length, maximum Gleason score, and extension of disease at positive surgical margins during radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 98-98.	0.8	0
348	Decreasing length of hospital stay following radical cystectomy using multimodal enhanced recovery protocol.. Journal of Clinical Oncology, 2014, 32, 313-313.	0.8	0
349	Venothromboembolism and radical cystectomy: Prevalence of risk factors and comparison of anticoagulation use.. Journal of Clinical Oncology, 2014, 32, 339-339.	0.8	0
350	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract. , 2015, , 153-178.		0
351	Radiosensitivity of orthotopic ileal neobladders.. Journal of Clinical Oncology, 2015, 33, 350-350.	0.8	0
352	Oncological outcomes in high-risk prostate cancer after radical prostatectomy based on Gleason score: USC experience with 3,755 cases.. Journal of Clinical Oncology, 2015, 33, 60-60.	0.8	0
353	Baseline GFR and cisplatin-induced renal toxicity in urothelial cancer patients.. Journal of Clinical Oncology, 2016, 34, 380-380.	0.8	0
354	Blue Light Cystoscopy with Cysview: The USC Experience. Videourology (New Rochelle, N Y), 2016, 30, .	0.1	0
355	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization.. Journal of Clinical Oncology, 2016, 34, e16001-e16001.	0.8	0
356	The opportunity cost (OC) of performing radical prostatectomy (RP) by low volume (LV) providers (Prov).. Journal of Clinical Oncology, 2016, 34, 6509-6509.	0.8	0
357	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy.. Journal of Clinical Oncology, 2016, 34, e16004-e16004.	0.8	0
358	An extraperitoneal midline approach to retroperitoneal lymph node dissection to minimize bowel morbidity.. Journal of Clinical Oncology, 2016, 34, e16042-e16042.	0.8	0
359	Frailty as a predictor of complications in older patients undergoing radical cystectomy.. Journal of Clinical Oncology, 2016, 34, e16007-e16007.	0.8	0
360	Female cystectomy with orthotopic urinary diversion: Is fear of urethral recurrence justified?. Journal of Clinical Oncology, 2016, 34, e16006-e16006.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Cell-free DNA (cfDNA) whole genome bisulfite sequencing in patients with muscle-invasive bladder cancer patient treated with cystectomy with curative intent.. Journal of Clinical Oncology, 2019, 37, 359-359.	0.8	0
362	Epigenomic profiling of plasma cell-free DNA (cfDNA) to predict bladder cancer recurrence after radical cystectomy.. Journal of Clinical Oncology, 2019, 37, e14525-e14525.	0.8	0
363	Retroperitoneal Lymph Node Dissection as an Alternative Treatment Strategy for Low Volume, Clinical Stage II Testicular Seminoma: A Survey of Patients and Providers. Urology Practice, 2019, 6, 249-255.	0.2	0
364	ERAS for Major Urological Procedures: Evidence Synthesis and Recommendations. , 2020, , 421-431.		0
365	Reply by Authors. Journal of Urology, 2022, 207, 313-313.	0.2	0
366	Re: Detection rate of CIS during TURBT following shift from PDD to NBI in a single University Hospital. Urology, 2022, , .	0.5	0